Retrospective Analysis of the Correlation Between Imaging Features and Pathology, Prognosis in Renal Tumors
Retrospective Analysis of the Correlation Between CT/MRI Imaging Features and Pathology, Prognosis in Patients With Renal Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Zhen Li
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Our hospital admits patients with renal tumors in the urology department. The diagnosis is confirmed through surgical pathology, and the patients' imaging data is obtained through contrast-enhanced Computed Tomography or Magnetic Resonance examination in the radiology department.
Exclusion Criteria:
- Patients who have undergone puncture, microwave, interventional therapies before the examination, or who have received chemotherapy or radiotherapy;
- Patients with poor respiratory coordination, resulting in significant image artifacts;
- Lesions are cystic, without discernible regions of interest, or with multiple regions of necrosis within the lesion;
- Lesions are too small, with a diameter of less than 1cm;
- Thin-slice imaging is not available in the CT scan.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
WHO ISUP grading high
high-grade refer to Grades 3 and 4 tumours with an unfavourable prognosis
|
extracted image features from CT or MRI
|
|
WHO ISUP grading low
low-grade refer to Grades 1 and 2 tumours with a promising prognosis
|
extracted image features from CT or MRI
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WHO/ISUP grade pathologically
Time Frame: 1 month
|
The WHO ISUP grade of the tumor indicated in the post-operative surgical pathology report
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pathological T stage
Time Frame: 1 month
|
pathological T stage according to the eighth TNM system.
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Li Dr, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TJ-IRB20230893
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.